NOVO NORDISK A/S |
Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
| 134.6 EUR | +0.13% |
|
+1.23% | +44.11% |
| 28.06. | Indien plant Anreize für Hersteller von Diabetes- und Adipositas-Medikamenten bis 2026, so ein Regierungsbeamter | RE |
| 28.06. | UBS hebt Ziel für Novo Nordisk auf 1100 Kronen - 'Neutral' | DP |
Kurzporträt
- Produkte zur Behandlung von Diabetes und Adipositas (92,6%);
- Produkte zur Behandlung seltener Krankheiten (7,4%): für die Behandlung von Hämophilie, Blutkrankheiten, hormonellen Störungen usw.
Der Nettoumsatz verteilt sich geographisch wie folgt: Europa/Naher Osten/Afrika (21,9%), Vereinigte Staaten (54,9%), Nordamerika (3,9%), China (7,2%) und Sonstige (12,1%).
Umsatz nach Geschäftsbereich
| DKK in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
Diabetes and Obesity Care
92,6
%
| 156 412 | 88,4 % | 215 098 | 92,6 % | +37.52% |
Rare Disease
7,4
%
| 20 542 | 11,6 % | 17 163 | 7,4 % | -16.45% |
Umsatz je Region
| DKK in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
United States
54,9
%
| 84 656 | 47,8 % | 127 534 | 54,9 % | +50.65% |
EMEA
21,9
%
| 44 236 | 25,0 % | 50 867 | 21,9 % | +14.99% |
Rest of the World
12,1
%
| 25 402 | 14,4 % | 28 078 | 12,1 % | +10.53% |
China
7,2
%
| 16 209 | 9,2 % | 16 687 | 7,2 % | +2.95% |
Canada
3,9
%
| 6 451 | 3,6 % | 9 095 | 3,9 % | +40.99% |
Manager
| Manager | Titel | Alter | Seit |
|---|---|---|---|
| Chief Executive Officer | 58 | 01.01.91 | |
| Director of Finance/CFO | 53 | 01.01.99 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01.10.15 |
Marcus Schindler
CTO | Chief Tech/Sci/R&D Officer | 57 | 01.01.18 |
| Chief Operating Officer | 54 | 01.01.92 | |
| Chief Tech/Sci/R&D Officer | 54 | 01.01.99 | |
Daniel Bohsen
IRC | Investor Relations Contact | - | 01.03.20 |
Tania Sabroe
HRO | Human Resources Officer | 47 | 01.01.07 |
| General Counsel | - | - | |
Sergey Manelis
PRN | Corporate Officer/Principal | - | 13.07.20 |
Aufsichtsräte
| Aufsichtsräte | Titel | Alter | Seit |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 19.03.15 |
Helge Lund
CHM | Chairman | 62 | 23.03.17 |
Martin MacKay
BRD | Director/Board Member | 68 | 01.03.18 |
Kasim Kutay
BRD | Director/Board Member | 59 | 23.03.17 |
Andreas Fibig
BRD | Director/Board Member | 62 | 01.03.18 |
Henrik Poulsen
BRD | Director/Board Member | 57 | 25.03.21 |
| Director/Board Member | 58 | 01.01.92 | |
Christina Law
BRD | Director/Board Member | 57 | 01.01.22 |
Thomas Rantzau
BRD | Director/Board Member | 52 | 22.03.18 |
| Director/Board Member | 59 | 24.03.22 |
Anteilsklasse
| Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
|---|---|---|---|---|---|
| Aktie A | 10 | 1 075 000 000 | 0 | 0 | 70,22 % |
| Aktie B | 1 | 3 386 519 207 | 3 133 044 416 ( 92,52 %) | 48 091 207 ( 1,420 %) |
Unternehmensbesitz
| Name | Aktien | % | Bewertung |
|---|---|---|---|
NOVO NORDISK A/S 1,45% | 49 118 207 | 1,45% | 6 629 209 828 $ |
NNIT A/S 17,50% | 4 375 000 | 17,50% | 68 770 275 $ |
INNATE PHARMA 12,14% | 9 817 546 | 12,14% | 26 964 577 $ |
Unternehmenskontakt
Konzerngesellschaften
| Name | Kategorie und Branche |
|---|---|
Novo Nordisk India Pvt Ltd.
 Novo Nordisk India Pvt Ltd. Medical/Nursing ServicesHealth Services Part of Novo Nordisk A/S, Novo Nordisk India Pvt Ltd. is a leading healthcare company founded in 1923 and headquartered in Denmark. The company is based in Bengaluru, India. Novo Nordisk's purpose is to drive change to defeat diabetes and other serious chronic diseases. |
Medical/Nursing Services
|
Velfærdsfonden for Novo Nordisk A/S
|
Investment Trusts/Mutual Funds
|
NNE A/S
 NNE A/S Engineering & ConstructionIndustrial Services Part of Novo Nordisk A/S, NNE A/S is a Danish company that supplies systems, consultancy and engineering services. The company is based in Soborg, Denmark. |
Engineering & Construction
|
World Diabetes Foundation
|
Investment Trusts/Mutual Funds
|
Novo Nordisk Health Care AG
 Novo Nordisk Health Care AG Pharmaceuticals: MajorHealth Technology Novo Nordisk Health Care AG engages in the production and distribution of chemical and pharmaceutical products as well as articles for diagnostic and therapeutic applications. It also specializes in the research in and development of products, therapeutic methods, and display techniques primarily used in the chemical, pharmaceutical, and diagnostic fields. The company was founded on August 10, 2000 and is headquartered in Zurich, Switzerland. |
Pharmaceuticals: Major
|
Novo Nordisk Finance (Netherlands) BV
|
Finance/Rental/Leasing
|
Novo Nordisk Region Europe A/S
 Novo Nordisk Region Europe A/S Financial ConglomeratesFinance Novo Nordisk Region Europe A/S holds ownership interests in other companies to undertake investment and financing activities. It offers service on an operational basis, including the placement of capital in companies and real estate. The company was founded September 14, 2001 and is headquartered in Bagsvaerd, Denmark. |
Financial Conglomerates
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
| % 1. Jan. | Kap. | |
|---|---|---|
| +55.32% | 815 Mrd. | |
| -6.75% | 352 Mrd. | |
| +13.56% | 314 Mrd. | |
| +10.68% | 303 Mrd. | |
| +16.57% | 242 Mrd. | |
| +2.04% | 224 Mrd. | |
| +13.31% | 218 Mrd. | |
| +8.48% | 168 Mrd. | |
| -2.81% | 159 Mrd. |
- Börse
- Aktien
- A3EU6F Aktie
- A3EU6F Aktie
- Unternehmen Novo Nordisk A/S
